Qsymia, Honestly Explained

What Is Qsymia?

Qsymia (pronounced kyoo-SIM-ee-uh) is the brand name for a fixed-dose combination capsule of phentermine and extended-release topiramate. It is manufactured today by Currax Pharmaceuticals, which acquired the drug from its original developer, Vivus, Inc. The FDA approved Qsymia on July 17, 2012 — the second weight-management medication approved that year and the first combination pill of its kind.

The drug is classified as an anti-obesity medication (AOM). It is not indicated for cosmetic weight loss, short-term dieting, or for people with a BMI under the approval threshold. Qsymia is prescribed as an adjunct to lifestyle intervention — meaning reduced-calorie eating and increased physical activity — not as a replacement for it.

Qsymia ships only through a certified mail-order network (formerly mandated by the REMS program and still standard practice with most prescribers) and is a Schedule IV controlled substance because of its phentermine content.

Ingredients: Phentermine + Topiramate

Qsymia's entire effect comes from the interaction of two ingredients that were already on the US market as single agents long before 2012. Each one carries its own pedigree — and its own baggage.

Phentermine (the stimulant half)

Phentermine is a sympathomimetic amine — a class of stimulants that act on the central nervous system to increase norepinephrine release. It was approved in 1959 and has been the most commonly prescribed weight-loss drug in the United States for more than half a century. It suppresses appetite, elevates heart rate, and raises blood pressure. It is a Schedule IV controlled substance on its own.

Phentermine is most famous as the "phen" half of the Fen-Phen combination pulled from the market in 1997 over cardiac valve concerns (that problem was traced to fenfluramine, not phentermine). Phentermine alone is labeled for short-term use — typically up to 12 weeks — though in practice, many prescribers use it longer under off-label monitoring.

Topiramate (the anti-seizure half)

Topiramate was approved in 1996 for epilepsy and in 2004 for migraine prophylaxis. Its weight-loss effect was noticed as an unwelcome side effect in seizure patients — they lost weight, often substantially. The exact mechanism by which topiramate suppresses appetite remains uncertain. Proposed pathways include modulation of GABA receptors, suppression of glutamate activity, carbonic-anhydrase inhibition, and altered taste perception.

Topiramate is not a controlled substance, but it carries a well-known side-effect profile that includes paresthesia (tingling in hands and feet), altered taste, cognitive slowing, and — critically — teratogenicity: first-trimester exposure is associated with a 2–5-fold increase in oral clefts. That risk is the reason Qsymia has its REMS program.

How Qsymia Works

Qsymia's weight-loss mechanism is often described as "appetite suppression," but that's a simplification. What the two ingredients actually do is best understood separately.

Phentermine stimulates the release of norepinephrine in the hypothalamus. Norepinephrine activates the "fight-or-flight" sympathetic pathway, which among other things suppresses the drive to eat. Patients on phentermine typically report a blunted hunger response, especially in the first half of the day, plus mild jitteriness, elevated resting heart rate, and sometimes insomnia.

Topiramate likely works through several converging mechanisms. The most supported theory is that it enhances GABA-mediated inhibition and reduces glutamate excitation in brain reward circuits. Patients often describe food — particularly highly palatable foods like sweets and carbonated beverages — as tasting "off" on topiramate. The drug also appears to reduce binge-eating behavior in controlled trials, suggesting a true behavioral shift beyond pure appetite suppression.

Taken together, the combination acts on both the drive to eat (phentermine) and the reward of eating (topiramate). This dual action is why the Qsymia combination tends to produce more weight loss than either drug alone at comparable doses.

Is Qsymia a GLP-1?

This is one of the most common questions we see, and it's understandable. Weight-loss medications are having a moment, and the terms get blurred in the news. Here is the actual comparison, drug class against drug class:

Because the mechanisms are different, the side-effect profiles are different. Qsymia's profile is driven by stimulation (elevated heart rate, insomnia, dry mouth) and topiramate's CNS effects (tingling, cognitive slowing). GLP-1 medications' side effects are predominantly gastrointestinal (nausea, constipation, diarrhea) and mostly occur during dose escalation, settling over weeks.

For a full head-to-head on efficacy, safety, and price, see our Qsymia vs GLP-1 comparison.

Who Qualifies for Qsymia

Per the FDA-approved labeling, Qsymia is indicated in adults and adolescents 12 years and older as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients who meet at least one of the following:

• Adults with a BMI ≥ 30 kg/m² (obesity), or
• Adults with a BMI ≥ 27 kg/m² (overweight) and at least one weight-related comorbidity: type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea
• Adolescents 12+ with BMI at or above the 95th percentile for age and sex (i.e., meeting the pediatric definition of obesity)

Contraindications — who should not take Qsymia

• Pregnancy (topiramate is teratogenic — oral clefts)
• Glaucoma (topiramate can cause acute angle-closure glaucoma)
• Hyperthyroidism (additive cardiovascular stimulation)
• Recent MAOI use (hypertensive crisis risk with phentermine)
• Known hypersensitivity to either ingredient

Relative contraindications — where the drug may still be used with caution — include coronary artery disease, uncontrolled hypertension, history of substance-use disorder, kidney stones, and metabolic acidosis.

How Much Weight Will You Lose?

The honest answer depends on dose, adherence, and what you're comparing against. Here's the pooled trial data, simplified:

Source: FDA approval package and CONQUER 56-week ITT analysis (Gadde KM et al., Lancet 2011; 377:1341–52).

These numbers are mean losses across large trial populations. Individual results vary substantially. Some patients lose 15–20%; others lose nothing. The most reliable predictor of long-term success is early response: patients who lose at least 3–5% of their starting weight in the first 12 weeks tend to continue losing, while patients who don't typically won't — which is why the label recommends discontinuation at 12 weeks in non-responders.

Side Effects Snapshot

A very condensed summary — the full side-effects page goes deeper. Frequencies below are from the 15/92 dose in pivotal trials:

• Paresthesia (tingling hands/feet) — ~20%
• Dry mouth — ~20%
• Constipation — ~16%
• Altered taste (especially carbonated drinks) — ~9%
• Insomnia — ~9%
• Dizziness — ~9%
• Cognitive slowing, word-finding trouble — ~6–8%
• Elevated heart rate — mean +1–2 bpm above baseline

Less common but clinically important: mood changes, depression, suicidal ideation (black-box adjacent — report any mood shift to your clinician), kidney stones, metabolic acidosis, and acute angle-closure glaucoma.

Controlled-Substance Status & REMS

The REMS (Risk Evaluation and Mitigation Strategy) program was originally created because topiramate exposure during the first trimester of pregnancy is associated with a 2–5-fold increase in the risk of oral clefts in newborns. The REMS requires prescriber certification, a patient-counseling document, and — for patients of reproductive potential — a negative pregnancy test before dispensing, plus monthly pregnancy testing during therapy. Certified mail-order pharmacies handle the majority of Qsymia fulfillment.

If you have never taken a Schedule IV drug before, this process can be surprising. For many patients, the administrative load is the single biggest reason they explore alternatives — which is part of why we wrote a dedicated guide to getting Qsymia and what the process looks like.

Dosing Basics

Qsymia is titrated upward over 14 weeks in a standard pattern. Skip the snapshot if you want the full dosing chart.

Take Qsymia in the morning to avoid insomnia. Do not split, chew, or open the capsules — topiramate is formulated as extended release.

What Qsymia Costs

Pricing varies. A snapshot, with the full cost breakdown covering coupons, insurance, and generic substitution:

• Brand Qsymia — roughly $220–$275 / month cash
• Generic phentermine/topiramate ER — roughly $55–$85 / month cash (available since 2022)
• Qsymia manufacturer savings card — can reduce brand price to $98/month for eligible patients
• Insurance coverage — inconsistent; weight-loss drugs are commonly excluded from formularies

Qsymia is typically the cheaper drug versus GLP-1s on paper. What the price tag doesn't capture is the cost-per-pound-lost ratio, the REMS administrative overhead, and the out-of-pocket cost of side-effect management (kidney-stone workups, glaucoma screenings, mood follow-up). For the full economic comparison, see our cost analysis.

The GLP-1 Alternative

If you're researching Qsymia in 2026, you are almost certainly also researching GLP-1 medications — semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and liraglutide (Saxenda). Here is the frank positioning, with no editorial flattery for either class:

Both classes are FDA-approved. Both have their use cases. Qsymia remains a reasonable option for patients who cannot tolerate GLP-1 GI side effects, or where price is the dominant constraint and a generic is acceptable. For most patients who ask us "which one should I take?" — and especially for patients who don't qualify for insurance-covered GLP-1 and are comparing cash prices — the modern GLP-1 telehealth route produces more weight loss, has a simpler risk profile, and does not involve controlled-substance paperwork.

Our full comparison page has the head-to-head numbers for Zepbound, Wegovy, Contrave, and standalone phentermine.